Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-cash Items (2016 - 2024)

Historic Non-cash Items for CytomX Therapeutics (CTMX) over the last 11 years, with Q4 2024 value amounting to $5.5 million.

  • CytomX Therapeutics' Non-cash Items fell 3657.76% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.5 million, marking a year-over-year decrease of 3657.76%. This contributed to the annual value of $5.5 million for FY2024, which is 3657.76% down from last year.
  • CytomX Therapeutics' Non-cash Items amounted to $5.5 million in Q4 2024, which was down 3657.76% from $8.7 million recorded in Q4 2023.
  • Over the past 5 years, CytomX Therapeutics' Non-cash Items peaked at $14.2 million during Q4 2022, and registered a low of $5.3 million during Q1 2021.
  • For the 5-year period, CytomX Therapeutics' Non-cash Items averaged around $6.9 million, with its median value being $6.1 million (2020).
  • As far as peak fluctuations go, CytomX Therapeutics' Non-cash Items skyrocketed by 13535.69% in 2022, and later tumbled by 3914.38% in 2023.
  • CytomX Therapeutics' Non-cash Items (Quarter) stood at $6.1 million in 2020, then fell by 1.48% to $6.1 million in 2021, then skyrocketed by 135.36% to $14.2 million in 2022, then plummeted by 39.14% to $8.7 million in 2023, then crashed by 36.58% to $5.5 million in 2024.
  • Its Non-cash Items stands at $5.5 million for Q4 2024, versus $8.7 million for Q4 2023 and $14.2 million for Q4 2022.